ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip OA

Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis

Theodore Korty, DO, & Adam Grunbaum, DO  |  April 15, 2020

A 59-year-old woman presented to our rheumatology clinic with a six-month history of a symmetric polyarthritis. She initially experienced pain in both knees. As time progressed, she began to notice pain in her ankles, hips, shoulders, hands and feet. She experienced joint stiffness lasting for more than 30 minutes every morning. She also described worsening…

Filed under:Conditions Tagged with:arthralgiasCancercase reportclubbinghypertrophic osteoarthropathy (HOA)

Yes, the FDA Employs Rheumatologists. Here’s Their Role.

Renée Bacher  |  April 15, 2020

Ever wonder what role physician regulators—rheumatologists, in particular—perform at the U.S. Food & Drug Administration (FDA)? “I am not sure that many practicing rheumatologists know there are clinicians who work for the FDA,” says rheumatologist Nadia Habal, MD, a medical officer in the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA. “It would…

Filed under:Drug Updates Tagged with:U.S. Food and Drug Administration (FDA)

New Processes May Stick Around After the Pandemic: Q&A with Wendy Ramey, BSPharm, RPh, CSP

Susan Bernstein  |  April 13, 2020

How are COVID-19 and physical distancing restrictions at work affecting rheumatology professionals? The Rheumatologist interviewed clinical pharmacist Wendy Ramey, BSPharm, RPh, CSP, to discuss how the pandemic has changed the way her staff supports rheumatologists at the University of Kentucky Specialty Pharmacy and Infusion Services, Lexington. Ms. Ramey describes how these unprecedented times affect patients,…

Filed under:Practice Support Tagged with:coronavirusCOVID-19Hydroxychloroquine (HCQ)MedicationpharmacistsarilumabTechnologytelemedicinetocilizumab

Amneal Running Out of HCQ Raw Material Due to Finnish Restrictions

Michael Erman & Anne Kauranen  |  April 10, 2020

NEW YORK/HELSINKI (Reuters)—Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the anti-malarial drug hydroxychloroquine (HCQ) that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker’s chief executives. Amneal has committed to producing about 20 million…

Filed under:Uncategorized Tagged with:COVID-19HCQHydroxychloroquine (HCQ)

A Collaborative Website as a Communication Model During the COVID-19 Pandemic

Sheryl Mascarenhas, MD, with Greg Stevens, BS  |  April 10, 2020

Under the onslaught of developing information on COVID-19, one health system found a way to streamline communication using a secure tool it already had access to.

Filed under:Information TechnologyPractice SupportTechnology Tagged with:COVID-19SharePoint

A Transition to 90% Telemedicine: Q&A with Karim Masri, MD

Susan Bernstein  |  April 9, 2020

How are COVID-19 and current restrictions on physical distancing affecting rheumatologists? The Rheumatologist interviewed Karim Masri, MD, to ask how the pandemic has changed the way he and his clinic staff deliver patient care, and how these unprecedented times affect patients, staff and life outside the office. Dr. Masri is a practicing rheumatologist at Bon…

Filed under:Practice Support Tagged with:coronavirusCOVID-19telemedicine

Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug

Matthias Blamont & Michael Erman  |  April 3, 2020

PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19HCQHydroxychloroquine (HCQ)Sanofi

Inflammation & Psych Issues: A Look at Potential Co-Morbidity

Mike Fillon  |  March 30, 2020

Rheumatic disease affects not just the body, but can also compound psychiatric disturbances, including depression, anxiety, fatigue and more, possibly making the underlying disease worse…

Filed under:Conditions Tagged with:comorbiditiesinflammationmindpsychiatric

ACR Advocates Against Payer Mandates on Specialty Pharmacy Acquisition of In-Office Treatments

From the College  |  March 23, 2020

In partnership with rheumatology and other specialty organizations, the ACR is working against payer and employer policies that mandate specialty pharmacy acquisition of in-office treatments.

Filed under:InsuranceLegislation & Advocacy Tagged with:COVID-19In-office treatmentinsurancepharmacy benefit managersspecialty drug acquisition

Enemy at the Gates: The Emerging Threat of COVID-19

Philip Seo, MD, MHS  |  March 23, 2020

On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

Filed under:ConditionsOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:COVID-19Philip SeoRheuminationsSeo

  • « Previous Page
  • 1
  • …
  • 129
  • 130
  • 131
  • 132
  • 133
  • …
  • 333
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences